Other conditions Board decisions

The Board denied service connection for nephrolithiasis and neutropenia, finding that the conditions are not related to military service or herbicide exposure.,Service connection was also denied for a total disability rating based on individual unemployability prior to May 1, 2014.

The Veteran's appeal for a total disability rating based on individual unemployability (TDIU) prior to January 3, 2017 is dismissed as he withdrew his appeal in response to the Supplemental Statement of the Case.

The Board denied service connection for T-cell prolymphocytic leukemia, finding no evidence of direct or presumptive service connection. The cause of death due to the condition was also denied.

The Veteran's claim for compensation under the provisions of 38 U.S.C. § 1151 for additional disability of respiratory symptoms (occasional shortness of breath, coughing, wheezing) as a result of VA's failure to diagnose and treat a pulmonary embolism during February 2004 VA hospitalization is granted.

The Veteran's skin condition, including chloracne, has been granted service connection.,The Veteran's vision condition is remanded for further development and opinion.

The Board has remanded the case due to the need for additional development regarding the Veteran's exposure to ionizing radiation during service, including a dose estimate and an examination to determine the nature and etiology of his multiple myeloma.

The Board has remanded the claims for a right eye disability, left leg disability, and right leg disability due to additional development being required.

The Board has granted service connection for right ulnar nerve damage and a right-hand old boxer fracture, finding that the onset of these conditions occurred during active service.

The Board has decided to remand the case due to insufficient evidence regarding the Veteran's exposure to Agent Orange and the relationship between his heart condition, specifically atrial fibrillation, and service. The AOJ is instructed to verify the Veteran's in-service exposure to herbicide agents and obtain a medical opinion on the etiology of his heart condition.

The Board dismissed the Veteran's claim for special monthly compensation (SMC) based on the need for regular aid and attendance as it was granted in a March 2022 rating decision.

The Veteran's Barrett's esophagus is found to be directly related to his service-connected obstructive sleep apnea, and the Board grants service connection for this condition.

The appeal was dismissed due to the Veteran's death, and no further action can be taken on this case.

The Board has determined that there was substantial compliance with the remand and thus the appeal must be remanded again due to inadequate VA examination. The Veteran's respiratory disorders, including emphysema and multiple spontaneous pneumothorax, are being reviewed for potential service connection based on in-service asbestos exposure.

The appeal for an apportionment of the Veteran's VA compensation benefits is dismissed due to the death of the Veteran.

The Veteran withdrew his appeal regarding service connection for osteoporosis of the spine, leaving no issues for further consideration.

The Board has determined that the procedural and due process rights of both parties have not been fully completed, and additional development is required to ensure proper consideration of all evidence. The case will be remanded for further action.

The Veteran's challenges to the validity of her overpayment amount and its creation are remanded due to ambiguity in her service dates and TAs.

The Veteran's gout has been productive of severely incapacitating exacerbations occurring four or more times a year, warranting a 60 percent disability rating.

The Veteran's child, R.B., was found to be permanently incapable of self-support prior to the age of 18 due to disabilities including ADHD and other mental health conditions. The Board granted recognition as a helpless child.

The Board has granted a higher initial rating of 20 percent for the Veteran's RIGHT lower extremity meralgia paresthetica of the femoral nerve, effective January 12, 2015.